Malvern, PA, June 17, 2019 – VenatoRx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. VenatoRx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents Discovery Summary Session.
VenatoRx’s presentations at ASM Microbe will take place as follows:
— Friday, June 21, 2019 —
New Agents Discovery Summary Session: Early New Antimicrobial Agents
Title: Orally Bioavailable Beta-lactamase Inhibitor VNRX-7145
Time: 9:50am - 10:10am PT
Presenter: Daniel C. Pevear, Ph.D., Senior Vice President, Biology, VenatoRx Pharmaceuticals
Location: 207/208 South
Pharma Pipeline Update: Part I
Title: VenatoRx Pipeline
Time: 3:03pm – 3:14pm PT
Presenter: Christopher J. Burns, Ph.D., President and CEO, VenatoRx Pharmaceuticals
Location: AAR Track Hub (Booth 5053) - Learn - Exhibit and Poster Hall
— Sunday, June 23, 2019 —
AAR08 - New Antimicrobial Agents (pre-Phase 2): Early Beta-Lactams and Beta-Lactamase Inhibitor Combinations
Poster Presentation | 11:00am – 1:00pm PT
Location: Exhibit and Poster Hall
- SUNDAY - AAR-719 — Rescue of Ceftibuten Activity by the Oral ?-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D ?-Lactamases. J. John, C.L. Chatwin, J.C. Hamrick, G. Moeck, D.C. Pevear.
- SUNDAY - AAR-720 — The Orally Bioavailable Beta-Lactamase Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten against Enterobacteriaceae Expressing Ambler Class A, C, and/or D Enzymes. C. Hamrick, C.L. Chatwin, K.J. John, G. Moeck, L. Xerri, D.C. Pevear.
- SUNDAY - AAR-721 — In Vitro Activity of Ceftibuten in Combination with VNRX-7145 and Comparators against 1,066 UTI Isolates Non-Susceptible to Amoxicillin-Clavulanate and Levofloxacin. Hackel, D. Sahm.
- SUNDAY - AAR-722 — Antimicrobial Activity of Cefepime in Combination with VNRX-5133 against a Global 2018 Surveillance Collection of Pseudomonas aeruginosa. Hackel, D. Sahm.
- SUNDAY - AAR-723 — Synergy/Antagonism of Ceftibuten/VNRX-7145 in Combination with Other Commonly Used Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic Bacteria, and Yeast.L. Chatwin, K.J. John, J.C. Hamrick, C.J. Burns, D.C. Pevear, G. Moeck.
- SUNDAY - AAR-724 — In Vitro Permeability and Metabolic Biotransformation of Oral Beta-Lactamase Inhibitor VNRX-7145 across Species.E. Trout, C.L. Chatwin, L. McLaughlin, J.C. Hamrick, G. Moeck, D.C. Pevear.
- SUNDAY - AAR-726 — Efficacy of Ceftibuten + VNRX-7145 a Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a Murine UTI Mode.E. Pulse, W. J. Weiss, P. Nguyen, D. Valtierra, K. Peterson, K. Carter, G. Moeck, R.E. Trout, J. Hamrick, D.C. Pevear.
- SUNDAY - AAR-727 — Assessment of the In Vivo Pharmacodynamic Profile of Ceftibuten/VNRX-7145 Combination against Serine ?-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Thigh Infection Model.M. Avery, K. Abdelraouf, D.P. Nicolau.
- SUNDAY - AAR-728 — Oral Bioavailability of Novel Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human Primates. Pevear, R. Trout, L. McLaughlin, J. Hamrick, G. Moeck.
CPHM02 - Antimicrobial Susceptibility Testing - Test Performance for New Agents
Location: Exhibit and Poster Hall
11:00am – 1:00pm PT
- SUNDAY - CPHM-860 — Impact of Variations in Susceptibility Testing Parameters on the In Vitro Activity of Ceftibuten in Combination with VNRX-7145. Hackel, D. Dressel, D. Sahm.
# # #
About VenatoRx Pharmaceuticals
VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. Founded in 2010, VenatoRx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs. VenatoRx has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Wellcome Trust, CARB-X, and the Defense Threat Reduction Agency (DTRA) as well as private equity investments from Versant Ventures, Abingworth, and Foresite Capital.
The Company’s most advanced development-stage product is VNRX-5133, an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases, including ESBL, OXA, KPC, NDM, and VIM enzymes. VenatoRx believes that VNRX-5133, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option to meet unmet medical need in patients with infections due to carbapenem-resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), suspected polymicrobial infections caused by both gram-negative and gram-positive susceptible pathogens, and engineerable MDR bioterror pathogens such as Burkholderia spp. and Salmonella spp. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx intends to initiate Phase 3 pivotal trials during the third quarter 2019. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300019C, and The Wellcome Trust under Award No. 360G-Wellcome-101999/Z/13/Z.
VenatoRx’s second development-stage product in clinical development is VNRX-7145, an orally bioavailable BLI that in a fixed combination with the third generation orally bioavailable cephalosporin, ceftibuten, has the potential to rescue activity of the partner antibiotic against ESBLs and key carbapenem-resistant Enterobacteriaceae, including those expressing KPC and OXA carbapenemases. This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.
Additionally, VenatoRx has a broad pipeline of preclinical programs including a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents targeting Hepatitis B Virus. For more information, please visit www.venatorx.com.